Details for Patent: 9,149,428
✉ Email this page to a colleague
Which drugs does patent 9,149,428 protect, and when does it expire?
Patent 9,149,428 protects DURYSTA and is included in one NDA.
This patent has twenty-three patent family members in ten countries.
Summary for Patent: 9,149,428
Title: | Processes for making cyclic lipid implants for intraocular use |
Abstract: | Biocompatible implants comprising a cyclic lipid therapeutic agent are made using a low temperature melt extrusion process. The implants are suitable for intraocular use to treat an ocular condition. |
Inventor(s): | Spada; Lon T. (Walnut, CA), Chang; James N. (Newport Beach, CA), Luu; Michelle H. (Anaheim, CA) |
Assignee: | Allergan, Inc. (Irvine, CA) |
Application Number: | 14/469,764 |
Patent Claim Types: see list of patent claims | Compound; Delivery; Device; |
Drugs Protected by US Patent 9,149,428
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Abbvie | DURYSTA | bimatoprost | IMPLANT;OPHTHALMIC | 211911-001 | Mar 4, 2020 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,149,428
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2007337139 | ⤷ Try a Trial | |||
Canada | 2673294 | ⤷ Try a Trial | |||
Denmark | 2124879 | ⤷ Try a Trial | |||
Denmark | 2712610 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |